Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBIT Margin: 2023-2025

Historic EBIT Margin for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to -1,157.61%.

  • Immunome's EBIT Margin rose 53482.00% to -1,157.61% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,784.14%, marking a year-over-year increase of 73435.00%. This contributed to the annual value of -3,382.37% for FY2024, which is 260102.00% down from last year.
  • Immunome's EBIT Margin amounted to -1,157.61% in Q2 2025, which was up 24.12% from -1,525.50% recorded in Q1 2025.
  • In the past 5 years, Immunome's EBIT Margin registered a high of -129.96% during Q3 2023, and its lowest value of -12,857.05% during Q1 2024.
  • Its 3-year average for EBIT Margin is -2,492.75%, with a median of -1,608.96% in 2025.
  • As far as peak fluctuations go, Immunome's EBIT Margin tumbled by 1,266,792bps in 2024, and later spiked by 1,133,155bps in 2025.
  • Immunome's EBIT Margin (Quarterly) stood at -2,473.94% in 2023, then tumbled by 55,637bps to -3,030.31% in 2024, then skyrocketed by 53,482bps to -1,157.61% in 2025.
  • Its EBIT Margin stands at -1,157.61% for Q2 2025, versus -1,525.50% for Q1 2025 and -3,030.31% for Q4 2024.